---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-002024"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:40:45.904697+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ironwood cuts FY2022 revenue guidance to ~$411M; issues FY2023 outlook and files sNDA for pediatric LINZESS

## Summary
- Updated FY2022: total revenue ~$411M (prev. $420-430M), LINZESS net sales ~0% growth, adj. EBITDA ~$250M.
- FY2023 guidance: revenue $420-435M, LINZESS net sales growth 3-5%, adj. EBITDA >$250M.
- sNDA submitted to FDA for LINZESS in functional constipation in children 6-17; if approved, first FDA therapy for this population.
- Expects ~$650M cash at YE2022; high single-digit LINZESS prescription demand growth in 2023.
- Clinical milestone: CNP-104 data expected in H2 2023.

## SEC filing metadata
- accession: 0001104659-23-002024
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465923002024/0001104659-23-002024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465923002024/tm232274d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-002024
- JSON: https://secwatch.observer/filing/0001104659-23-002024.json
- Plain text: https://secwatch.observer/filing/0001104659-23-002024.txt

## Key facts
- Earnings Releases
  IRONWOOD PHARMACEUTICALS INC reported full year 2022 results: revenue ~$411 million. Guidance reaffirmed.
  - Period: full year 2022
  - Revenue: ~$411 million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: expects: Previous 2022 Guidance (November 2022) Updated 2022 Guidance 1 LINZESS U.S. net sales growth 2 Low single digits % ~0% Total revenue $420 - $430 million ~$411 million Adjusted EBITDA 3 >$250 million ~$250 million Full Year 2023 Financial Guidance The table below summarizes Ironwood’s full year 2023 guidance. Ironwood expects: 2023 Guidance
  evidence_url: https://www.sec.gov/Archives/edgar/data/1446847/000110465923002024/0001104659-23-002024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.